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Cardiovascular diseases (CVDs) have been the prime cause of mortality worldwide for decades. However, the underlying
mechanism of their pathogenesis is not fully clear yet. It has been already established that reactive oxygen species (ROS) play a
vital role in the progression of CVDs. ROS are chemically unstable reactive free radicals containing oxygen, normally produced by
xanthine oxidase, nicotinamide adenine dinucleotide phosphate oxidase, lipoxygenases, or mitochondria or due to the uncoupling
of nitric oxide synthase in vascular cells. When the equilibrium between production of free radicals and antioxidant capacity of
human physiology gets altered due to several pathophysiological conditions, oxidative stress is induced, which in turn leads to
tissue injury. This review focuses on pathways behind the production of ROS, its involvement in various intracellular signaling
cascades leading to several cardiovascular disorders (endothelial dysfunction, ischemia-reperfusion, and atherosclerosis), methods
for its detection, and therapeutic strategies for treatment of CVDs targeting the sources of ROS.The information generated by this
review aims to provide updated insights into the understanding of the mechanisms behind cardiovascular complications mediated
by ROS.
1. Chemical Characteristics of
Reactive Oxygen Species (ROS)
Researchers have been continuously studying the potential
role of oxidative damage in cardiovascular diseases (CVDs)
for a few decades. In a simple term, the common risk factors
for CVDs like diabetes mellitus, smoking, aging, hyperc-
holesterolemia, and nitrate intolerance can further increase
the possibility of the generation of ROS. Furthermore, these
risk factors can trigger several pathways such as apoptosis
of endothelial cells (EC), expression of adhesion molecules,
activation of metalloproteinases, induction of proliferation
and migration of smooth muscle cells, lipid peroxidation,
and change in vasomotor functions, collectively leading to
CVDs [1, 2]. ROS are chemically reactive molecules con-
taining oxygen. Several ROS with unpaired electrons, for
instance, superoxide anion (O
2
∙−), hydroxyl radical (OH∙−),
and lipid radicals, are considered as free radicals. ROS,
such as hydrogen peroxide (H
2
O
2
), peroxynitrite (ONOO−),
and hypochlorous acid (HOCl), are not free radicals but
possess an oxidizing effect resulting in oxidant stress. A
chain reaction leads to the production of many reactive
oxygen species from one ROS (Figure 1). For example, the
reactions of radicals and fatty acids (polyunsaturated fatty
acids, PUFAs) within the cytoplasmic membrane result in
a fatty acid peroxyl radical which can attack the adjacent
side chain of the fatty acid and commence production of
other lipid radicals. Lipid radicals generated in this chain
reaction get collected in the plasma membrane and may have
an innumerable effect on cell function, including alteration in
cell membrane permeability and dysfunction of membrane-
bound receptors [1, 3].
2. Potential Sources of ROS for CVDs
In a physiological system, the imbalance between antioxidant
defense mechanism and ROS production leads to oxidative
stress and subsequent pathological conditions [4]. Most
prominent ROS causing toxic insult to the human body are
H
2
O
2
, O
2
∙−
,
∙OH, and ONOO− [5]. In the blood vessel wall,
each layer can produce ROS in pathological conditions [6].
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Figure 1: Production of ROS.The figure shows the pathway of ROS
production in the humanbodywith various enzymes involved. SOD:
superoxide dismutase; MPO: myeloperoxidase.
Wattanapitayakul and Bauer reported that, within mitochon-
dria, oxygen is usually utilized for energy production (in
the form of ATP) and oxidative phosphorylation. During
the mitochondrial electron transport (MET), harmful ROS
are formed but they are balanced by antioxidant defense.
However, in case of ischemia or hypoxia, MET is imbalanced,
leading to ATP depletion, acidosis, mitochondrial depolar-
ization, collection of noxious metabolites, intracellular Ca2+
overload, and cell death [7]. For example, approximately 1–
3% of molecular oxygen is converted to unstable/reactive
O
2
∙− inmitochondrial complexes I and III through a pathway
involving oxidative phosphorylation [8]. In general, cardiac
myocytes consume a high level of oxygen due to considerable
higher number of mitochondria than other cells [9]. For
this reason, cardiac myocytes also release ROS and cause
oxidative stress to other cells [10]. But ROS do not have only
a negative side, since production of ROS at physiological
levels promotes cellular activities, controls the hormone level,
maintains chemical balance, strengthens synaptic plasticity,
and induces enzymes. Moreover, ROS also helps to fight
against invading pathogens and induce an immune response
against the pathogenic influence [5]. To a certain extent, ROS
are neutralized by intracellular antioxidant enzymes such as
glutathione peroxidase (GPx), superoxide dismutase (SOD),
and catalase and consumption of other nonenzyme antiox-
idants like 𝛽-carotene, ascorbic acid, and tocopherols as a
supplement [7]. In spite of being necessary to carry out cell
signaling pathways, overproduction of ROS leads to injury
of the cell membrane integrity causing altered permeability,
change in proteins expression, and DNA damage [11]. For
the majority of CVDs, the enzymatic sources of ROS include
NAD(P)H oxidase, lipooxygenase, cyclooxygenase (COX),
xanthine oxidase (XO), uncoupled nitric oxide synthases
(NOS), cytochrome P450, and mitochondrial respiration
[12–14] (Figure 2). The process of increased O
2
∙− genera-
tion, facilitated by XO enzyme, can be antagonized by a
therapeutic approach with XO inhibitor, like allopurinol, to
ameliorate cardiac conditions [15]. NADPH oxidase (Nox),
commonly found on the cellular membrane, is stimulated
during phagocytosis leading to increased ROS release [10].
In particular, the overexpression of Nox2 and Nox4 is linked
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Figure 2: Sources of O
2
∙− and H
2
O
2
in cells. The figure shows
the enzymatic pathway of superoxide anion (O
2
∙−) and hydrogen
peroxide (H
2
O
2
) generation in cells.
to the remarkable oxidative stress observed during CVDs.
A study done by Kuroda et al. showed that Nox4 knockout
mice showed a low level of cardiac O
2
− revealing that Nox4
is a potential source of superoxide in cardiac myocytes.
Nox4 overexpression worsened the cardiac function and
induced apoptosis and fibrosis in a mouse with response
to pressure overload. Thus, Nox4 is a key contributor of
oxidative stress in themitochondrial redox systems leading to
cardiac impairment during pressure overload. Therefore, the
physiological role of Nox, translocating electrons throughout
the membrane, can be deregulated in CVDs leading to
cardiac dysfunction [16]. However, some pathways associated
with ROS mediated CVDs are yet to be clarified. However,
researchers are trying to reveal good, bad, and ugly roles
of ROS in the physiological system. In contrast to the
good face of ROS on signaling and immune response, at
high concentrations, ROS can exhibit the deleterious effect
on redox homeostasis leading to intracellular components
damage as seen in neurodegenerative diseases, CVDs, and
pulmonary disorders [5].
3. Oxidative Stress and
Endothelial Dysfunction
Endothelial cells are lining the interior surface of blood and
lymphatic vessels cells. Endothelial cells play an important
role in homeostasis and immune and inflammatory reactions.
EC regulates vascular tone by releasing various vasodila-
tor factors such as nitric oxide (NO) endothelium derived
hyperpolarizing factor, prostacyclin or vasoconstrictive fac-
tors such as thromboxane (TXA
2
), and endothelin-1 (ET-
1). Endothelial dysfunction (ED) is a pathological state of
the endothelium, which is a predictor of various CVDs, and
is caused by imbalance between vasodilating and vasocon-
stricting substances [17]. ROS are considered as signaling
molecules that contribute to ED in experimental and clinical
atherosclerosis [3, 18]. NO is a potent vasodilator produced
by the endothelium. Besides vasorelaxation, nitric oxide
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exerts various functions like antiplatelet, antithrombotic, and
anti-inflammatory properties and permeability decreasing
properties [19]. It is reported that ONOO− which is formed
by the reaction of superoxide and free radical NO can oxidize
tetrahydrobiopterin. If formed in a small amount, ONOO−
exerts a similar physiological activity like NO. However, at a
high concentration, it shows injurious activity by converting
to harmful peroxynitrous acid and causing alteration of
protein structure [20]. ED is associated with polymorphisms
of various genes which include cytochrome P450, methylene
tetrahydrofolate reductase, p22phox, angiotensin convertase
enzyme, and glutathione-S-transferase [21]. Excess amount
of ROS damages the endothelium, especially the terminal
arteries leading to alteration of the intracellular reduction-
oxidation homeostasis [22]. In a patient with diabetes mel-
litus, small vessel disease linked with mitochondrial disor-
ders might also be due to oxidative stress. The result of
diabetes mellitus in atherosclerosis is stimulated mainly by
oxidative stress [23]. ROSmay also activatemitogen activated
protein kinase, which regulates the expression of monocyte
chemoattractant protein 1 (MCP-1) and favors the chemotaxis
of circulating monocyte to the site of atherosclerotic lesion.
This demonstrates a potential link between arterial wall strain
and atherosclerosis [24].
4. ROS in Ischemia-Reperfusion (I/R) Damage
Several researches support the fact that ROS are involved
in ischemic occlusion leading to cardiac damage [39, 40].
Apart from carrying out the function of cellular O
2
storage
and supply by oxymyoglobin (Mb), it also acts as a potent
preventive source against I/R injury [40]. During the outset
of I/R injury, O
2
∙− release has been observed in an isolated
rat heart. Zhu and Zuo speculate that generation of O
2
∙− is
linked with Mb because of the lower myocardium oxygen
tension. Results revealed that the rise of fluorescence in the
ischemic heart was terminated by a SOD mimic, carbon
monoxide (CO), or byMb gene knockout. Likewise, O
2
∙− was
not formed in intracellular EC but rather from the myocytes,
which are considered a potential source of Mb. This suggests
that Mb is an important factor responsible for production of
O
2
∙− during ischemia [40]. An enzyme responsive to stress,
named sirtuin-6 (SIRT6), displays cardiac protection from
I/R injury as revealed in partial SIRT6 knockout mice as well
as in vitro cultured cardiomyocyte. SIRT6 is a deacetylase and
mono-ADP ribosyltransferase enzyme responsive to oxida-
tive stress and can protect the cell against oxidative stress.This
protective activity was achieved by initiating the expression
of catalase and manganese SOD antioxidant-encoding gene
resulting in reduced cellular oxidative stress [41]. Restoration
of the coronary artery blood flow reverse to the ischemic
myocardium can have a detrimental effect on the microvas-
cular function, causing arrhythmias [42]. In the endothelium,
the rise of ROS release and the opening of mitochondrial
permeability transition (MPT) pore play an important role
in the protection from I/R damage [43]. However, Kim and
Lemasters showed that mitochondrial ROS, accompanied
by normalization of pH, stimulate initiation of MPT pore
followed by death of myocytes after reperfusion. However,
Ca2+ overloading does not promote onset of MPT pore [44].
Research demonstrated that the reason behind the protective
effect was the involvement of ROS and potent vasodilator NO
in regulating downstream pathways by stimulating adenosine
triphosphate sensitive potassium channel in mitochondria
[45]. After open cardiac surgery, the I/R injury can influence
postsurgical consequences because of the lipid peroxidation
mediated by ROS [46]. In comparison to the heart obtained
from juvenile rat, the cardiac dysfunction due to I/R was
dramatically concealed in the heart obtained from congenital
heart disease (CHD) model rats. Moreover, the ratio of n-
3/n-6 PUFA was remarkably raised in I/R phase in CHD rats,
whereas it was not observed in juvenile rats suggesting that
the rise in n-3/n-6 ratio could result in the upregulation of
cell defense system against oxidation via n-3 PUFA oxidation
product 4-hydroxy-2-hexenal causing higher tolerance to I/R
damage [46].
5. ROS and Atherosclerosis
Excess production of ROS plays an important role in inflam-
mation, disturbed blood flow/abnormal shear stress, and
arterial wall remodeling. ROS causes remodeling through
proliferation of smooth muscle cell and increased inflamma-
tion [39]. Repeated continuous exposure to nonstreamline
shear stress of arterial regions generates O
2
induced by
endothelial Nox resulting in adhesion of monocytes [47].
The upregulation of adhesionmolecules including P-selectin,
VCAM-1, and E-selectin causes further inflammation by
adhesion of white blood cells. Development of inflammatory
response increases ROS production by phagocytosis, which
is important in the early stage of atherosclerosis [48, 49].
The Nox family of superoxide producing proteins is an
important source of ROS in signal transduction. Nox are
found to be expressed in phagocytic cells, EC, smoothmuscle
cells, and fibroblasts. Experiments conducted on arteries
from human volunteers with coronary artery disease and
animal experimental model with hypertension, diabetes, or
atherosclerosis demonstrated that Nox1, Nox2, and Nox5
stimulate endothelial dysfunction, inflammation, and pro-
grammed cell death; however, isoform Nox4 protects the
vascular system by increasing bioavailability of nitric oxide
and stoppage of cell death pathways [50]. Some research
presents the controversial role of Nox4 displaying either
protective or a deleterious role of Nox4.
Nox4 are found abundantly in kidney, vascular cells, and
osteoclasts [16]. Angiotensin II type 1 receptor activation and
hypertension are linked to increased expression of Nox1 and
Nox4 that could lead to vascular damage during chronic
hypertension [51]. MCP-1 is essential for the formation of
endothelial cell tumors (hemangioendotheliomas) which is
redox sensitive. It was found that only the Nox4 isoform was
present in endothelial cell tumors cells whereas knockdown
of Nox4 gene remarkably decreased the expression of MCP-
1 as well as hemangioendothelioma formation. This was
due to the fact that, in hemangioendothelioma cells, Nox4
delivers H
2
O
2
to the nuclear compartment causing oxidative
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alteration of DNA [52]. Inflammation mediates all stages of
atherosclerosis and ROS sources might include infiltrated
monocytes/macrophages, dysfunctional EC, and smooth
muscle cells thatmigrated from tunicamedia to tunica intima
layers of the wall of an artery. ROS oxidized-LDL is available
in the arterial wall and macrophages scavenge it resulting in
the formation of foam cells.This is one of the important steps
in the progression and development of atherosclerosis [53].
Also, the calcium-dependent zinc containing endopeptidase,
matrix metalloproteinase, secreted from EC, foam cells, and
vascular smooth cells, is activated during oxidative stress
in part due to inflammation and nonlaminar shear stress,
resulting in the ruptures of thrombosis [54].
6. Oxidative Stress and Mitochondria
Mitochondria play an important role in cellular signal-
ing pathways, particularly in the modulation of calcium
stores within the cell, generation of ROS, respiration, and
biogenesis. So, changes in mitochondrial function lead to
development of human diseases [55, 56].Mitochondrial DNA
(mtDNA) damage is linked to the atherosclerotic lesions in
apolipoprotein E (apoE) knockout mice and also introduces
atherogenesis in young apoE knockout mice [57]. Raised
levels ofmtDNAdamage have been seen in the vascular tissue
of CVD patients [58]. Mitochondrial dysfunction is due to
decreased manganese SOD, increased damage of mtDNA,
and increased atherosclerosis in apoE knockout mice [59].
There is excessive mitochondrial damage in atherosclerosis
model. Oxidized-LDL stimulates mitochondrial complex I
activity which depends on the induction of oxidative stress
[60, 61]. Composed of 46 subunits, human mitochondrial
complex I is the key enzyme responsible for oxidative
phosphorylation.Dysfunction of themitochondrial oxidative
phosphorylation in a physiological system is responsible for
occurrence of CVDs in humans, and mitochondrial diseases
are linked to mitochondrial respiratory-chain pathologies
and mutations of mitochondrial DNA. Studies reported that
various stress induced in the cells causes structural and
functional disturbance ofmitochondria [62, 63]. Dysfunction
of mitochondria provokes a signaling pathway for cell death
resulting in organ failure and diseases. Mitochondria based
pathological conditions including obesity, cancer, stroke,
diabetes, neurodegenerative diseases, heart failure, and aging,
however, are caused by intrusion of mitochondrial Ca2+,
ATP, or ROS metabolism [61, 63]. Myocardial ischemia-
reperfusion injury leads to mitochondrial Ca2+ overload and
consequent generation of ROS and opening of the mito-
chondrial permeability transition pore [60–62], resulting
in apoptosis. Compounds which can reduce mitochondrial
Ca2+ overload, decrease mitochondrial ROS collection, and
prevent mitochondrial energy generation are all potential
sources of therapies for preventing disease. Mitochondria
produce oxidative stress which plays an important role in
mediating programmed cell death (apoptosis) and damage
to mtDNA and leads to human aging, cancer, and CVDs.
Oxidative damage of the mitochondrial membrane results
in depolarization of membrane and uncoupled oxidative
phosphorylation and altered cellular respiration. Altered
mitochondrial respiratory chain can hinder the pivotal role
of providing the energy to the cell as ATP, leading to various
disease progression [60–64].
7. Methods for Detection of ROS in CVDs
Since ROS are highly unstable and very reactive, researchers
always face the problem of precisely monitoring them in
biological systems. One way to find out the possibility of
ROS in CVDs subjects involves exploring experimental proof
of oxidative reactions. Fluorescent probes and electron spin
resonance probes tools for detection of ROS are limited in
animal and human experiment due to technical problems
[65]. The following list of direct methods can show at least
in part indirect evidence of ROS effect in CVDs (Table 1).
7.1. Biomarkers of ROS
7.1.1. Lipid Peroxidation Mediated by ROS. LDL collects in
the blood vessels walls and lipid species undergo oxida-
tion in the presence of several ROS [66]. It is reported
that oxidative modification of LDL plays an important role
in the atherosclerosis process [67]. Macrophages take up
oxidized-LDL through scavenger receptor pathways resulting
in cholesterol ester-rich foam cells and EC dysfunction, in
part, by role of lectin-like oxidized-LDL receptor-1 [68, 69].
In atherosclerotic plaques, the availability of oxidized-LDL
has been observed by using immunohistochemical staining
for modified primary apolipoprotein B-100, the protein
moiety in LDL [38]. Elevated levels of autoantibodies against
oxidized-LDL or malondialdehyde-modified LDL particles
are linked to atherosclerosis and coronary artery diseases
(CADs) including acute coronary syndrome. In healthy
people, circulating levels of oxidized-LDL can be identified
by techniques such as ultrasound while in diseased subjects it
is commonly seen in clinical case of CAD [70–72].
7.1.2. MPO. High levels of the enzyme myeloperoxidase
which produces hypochlorous acid (HOCl) are found in
human atheroma and are an important predictor of CAD, as
well as in patients with unstable angina and mitochondrial
infarction (MI). Increased numbers of myeloperoxidase-
expressing macrophages are found in eroded or ruptured
plaques [73]. Also, MPO and hypochlorite-modified proteins
are colocalized in atherosclerotic lesions. Also, in human
study research, strong inverse relation occurs between MPO
serum concentrations and brachial artery flow-mediated
dilation, which is another clinical marker of atherosclerosis
[73, 74]. So, lowering MPO levels could lower occurrence
of CVDs. Human studies have demonstrated that humans
with total or near-total deficiency of MPO have a lower
chance of developing CADs [73]. Reduced expression of
MPO by its gene promoter polymorphism showed reduced
CADmanifestations but increased MPO expression by MPO
gene promoter polymorphism demonstrated raised CAD
[75]. Since the level of plasma MPO is sensitive to heparin
dosing [76], neutrophil activation [77], and the procedure
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Table 1: Direct methods for detection of ROS in CVDs.
Methods ROS detected Applications/mechanism Reference
Fluorescent protein-based
redox probes
Cytoplasmic and
mitochondrial H
2
O
2
Used to detect redox status and ROS by introducing
adenoviruses or plasmids inside cells. Afterwards, cells form
chimeric proteins efficient to detect alteration in the redox
status or ROS.
[25, 26]
Dihydroethidium (DHE) and
mitochondrion-targeted
probe mitoSOX
Cellular and mitochondrial
O
2
∙−
Can detect mitochondrial O
2
∙− by adding a
triphenylphosphonium group for promoting its collection in
the mitochondria. Similar to DHE, mitoSOX reacts with O
2
∙−
to give 2-hydroxy-mito-ethidium (2-OH-Mito-E+) so as to
be identified and measured using HPLC.
[27–29]
Cyclic hydroxylamine spin
probes
Total cellular and
mitochondrial O
2
∙−
Allows measurement of O
2
∙− in tissue, in in vitro cells, and in
vivo. [30–32]
Boronate-based fluorescent
probes H2O2 and ONOO
∙−
As probes have a fluorophore which is secured by boronate,
when subjected to H
2
O
2
, the boronate encounters a
nucleophilic attack, followed by its displacement from the
fluorophore, thus causing emission of light.
[33, 34]
Immunospin trapping
Free radical adduct
formation in the
mitochondria, cells, and
tissue samples
5,5-Dimethyl-1-pyrroline-N-oxide reacts with protein
radicals to form epitopes which can be particularly
characterized immunologically.
[35, 36]
In vivo using X- and L-band
ESR spectroscopy
Short-lived free radicals in
whole living animals
Detection is done in vivo by infusion of cyclic
hydroxylamines or nitrone spin traps, followed by ex vivo
study of the tissue or blood using X-band (9GHz) electron
spin resonance spectroscopy.
[37, 38]
of collection [78], there is a need for development of an
appropriate method for its sampling.
7.1.3. Plasma F2-Isoprostanes. F2-isoprostanes are considered
as the best biomarkers of oxidative stress status and lipid
peroxidation in an in vivo model. F
2
-isoprostanes are found
in an esterified form in normal biological tissues and are
available in free form in biological fluids, demonstrating
“physiological” levels of oxidative stress. The F
2
-isoprostanes
might be produced from membrane phospholipids or circu-
lating LDL [79, 80].The generation of F
2
-isoprostanes can be
via the action of several cell types like monocytes which are
involved in atherosclerosis and the oxidized products have
been restricted to a particular area within foam cells and
atherosclerotic plaques individual specimens [81]. Various
human studies have demonstrated a link between CAD and
isoprostane levels [82]. Raised levels of isoprostanes in urine
are an independent risk factor of CAD and are found to be
increased in patients having unstable angina. Raised levels of
isoprostanes are important markers of ischemic tissue injury,
chronic heart failure, congestive heart failure, and cardiac
remodeling [79, 82, 83]. Therefore, F
2
-isoprostanes could be
used for the prediction of cardiovascular events.
8. Molecular Role of ROS in
Muscle Contraction
During skeletalmuscle contraction, ROS are generatedwhich
can affect muscle adaptation and function. Zuo et al. studied
whether ROS are generated in the process of muscle contrac-
tion in isolated single skeletal muscle fibers (using Xenopus
laevis muscle), as well as whether these ROS generated by
contraction have an impact on fatigue development. To detect
the ROS generation, myofibers were loaded with fluorescent
probe (dihydrofluorescein-diacetate) which reacts with ROS
to form fluorescein. Fluorescein signal was raised remarkably
in both the first (42 ± 14%) and the third periods (39 ± 10%)
of maximal tetanic contraction. However, with the treatment
of reference antioxidant compound, ebselen, there was no
rise of fluorescein during the second contractile period
suggesting that ROS generation is high during contractile
activity and antioxidant treatment can halt ROS production
without any effect on myofiber contractility [84]. In spite
of the various pathways of ROS generation, the study of
key pathways of their production is still undergoing. In
particular, ROS generation in response to exercise, hypoxia,
and heat in the diaphragmatic skeletal muscle (a key muscle
during respiration) is a topic of interest [85, 86]. During
the state of heat stress, O
2
∙− is generated by skeletal muscle
which can be quantified by cytochrome 𝑐 reduction as it is
correlated with arachidonic acid metabolism. The blockage
of enzyme phospholipase A
2
using manoalide remarkably
reduced O
2
∙− release. However, neither the blockage of
COX with nonselective COX inhibitor indomethacin nor
the blockage of CYP P-450 contingent monooxygenase with
SKF-525A reduces O
2
∙− generation. In contrast, lipoxygenase
blockage with common inhibitors cinnamyl-3,4-dihydroxy-
𝛼-cyanocinnamate and 5,8,11,14-eicosatetraynoic acid dras-
tically halted the signal. Moreover, O
2
∙− generation was
notably reduced by diethylcarbamazine (5-LOX inhibitor)
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suggesting that metabolism of arachidonic acid involving
LOX is a key mediator of generation of extracellular O
2
∙−
in skeletal muscle [86]. The role of ROS in myocardial I/R
injury has been widely studied [87]. Vanden Hoek et al.
proposed the generation of a high amount of ROS in case
of ischemia before reperfusion by an in vitro experiment in
isolated cardiomyocyte during simulated I/R. The fluores-
cent probes 2󸀠,7󸀠-dichlorofluorescein and dihydroethidium
(DHE) were significantly oxidized during ischemia, revealing
ROS production. After an hour of ischemia, reperfusion leads
to further generation of OH− and H
2
O
2
. In contrast, treat-
ment of antioxidant compounds (1,10-phenanthroline and 2-
mercaptopropionyl glycine) during ischemia injury halted
oxidant production, raised the viability of cardiomyocytes,
and opposed contraction following ischemia. The ROS pro-
duction in response to residual O
2
as in case of ischemia
causes cellular injury observed in the reperfusion stage [88].
In a similar study on cardiomyocytes model of ischemia
performed by Becker et al., an inhibitor of mitochondrial site
III (myxothiazol) reduced oxidation. However, the inhibitor
of mitochondrial site IV (cyanide) along with NOS inhibitor
(nitro-L-arginine methyl ester), XO inhibitor (allopurinol),
and Nox inhibitor (apocynin) showed no effect, suggesting
that excessive O
2
∙− production is observed in ischemia prior
to reperfusion through ubisemiquinone area of the MET
chain [89]. Another study suggests that sublethal H
2
O
2
production in isolated cardiomyocytes during the period
of simulated ischemia modulates cell death later in reper-
fusion step, mainly due to the burst of reperfusion oxidant
[90].
9. Therapeutic Strategy Targeting ROS
Sources in CVD
9.1. Antioxidant. Antioxidants are a prime choice to fight
against ROS.Therefore, it is crucial to formulate the strategies
to halt abnormal ROS production inside the human body
as well as improve innate antioxidant protection capacity. A
cross-sectional research performed by Lane et al. reported
that dietary supplements of vitamins E, C, and A help to
lower occurrence of peripheral arterial disease [91]. Regular
consumption of diet rich in vegetables and fruits (as a
source of antioxidant vitamins) lowers the prevalence of
CVDs, and, globally, it is recommended for enough daily
intake of vegetables and fruit [92, 93]. These antioxidants
vitamins A, C, and E, CoQ10, lycopene, and quercetin
have been studied to explore their therapeutic and/or
preventative effects on ventricular remodeling, atheroscle-
rosis, heart failure, myocardial infarction, and ischemia-
reperfusion heart injury [94–97]. Various herbal plants such
as Nelumbo nucifera [98], Juglans regia [99], and Rumex
nepalensis [100] are a rich source of compounds exhibiting
remarkable antioxidant activity along with cardioprotective
activity. Among the antioxidants, the most commonly used
vitamin C and vitamin E as a cardioprotective supplement
are discussed in the following section also including the
information about their failure to revert the CVDs in some
study.
9.1.1. Vitamin C. It is well known that vitamin C helps in
regulation of blood pressure. A considerable study favors
the notion that vitamin C restores high blood pressure
related baroreflex dysfunction [101–103]. Some study revealed
that oxidative stress decreases the baroreflex sensitivity
leading to the constant hypertensive state. As shown in a
hypertensive rat model by Botelho-Ono et al., treatment of
vitamin C (150mg/kg, IV) remarkably lowered heart rate,
with improvement in baroreflex sensitivity compared to the
untreated hypertensive group. Also, treatment of NADPH
oxidase inhibitor apocynin (30 𝜇g/kg, intravenous) main-
tained baroreflex sensitivity revealing that ROS generated
via NADPH oxidase pathway plays a key role in the mod-
ification of baroreflex sensitivity in hypertension, whereas
treatment of antioxidants (vitamin C) restored this change
[102]. Similarly, Nishi et al. [101] also reported that chronic
administration of vitamin C at a dose of 150mg/kg/day
drastically lowers the mean arterial pressure (MAP) in a
hypertensive rat’s model as compared to vitamin C untreated
rat. Furthermore, the study also revealed increased expres-
sion of angiotensin II type 1 (AT-1) receptor in vitamin C
untreated hypertensive rat, with downregulation of AT-1 in
the vitamin C-treated group. Likewise, in a human clinical
trial, Bruno et al. showed that IV infusion of vitamin C
(3 g, over 5min) significantly reduces both sympathetic nerve
activity and blood pressure in essential hypertension patients
(𝑛 = 32) but not in normotensive patients (𝑛 = 20). This
study highlights the notion that the decrease in heart rate and
sympathetic nerve activity leading to reduced blood pressure
after application with vitamin C was because of makeover of
baroreflex function [103]. Endothelial dysfunction, a cause of
CVDs, is corrected in a human study (𝑛 = 93) by treatment
with vitamin C (2 g) alone or in combination with vitamin E
(600mg) as shown by Uzun et al. Results showed enhanced
vasodilation following an endothelium dependent pathway
in the radial artery of a subject with coronary artery disease
receiving vitamin C and/or vitamin E [104]. Vitamin C pro-
motes synthesis and deposition of collagen (type IV) in the
basementmembrane of EC, induces endothelial proliferation,
scavenges radicals to prevent EC apoptosis, and increases
endothelial NO production. However, there is variation in
the beneficial effect of synthetic vitamin C and natural (food-
derived) vitamin C on CVDs. One reason may be that,
along with dietary vitamin C (from fruits and vegetables),
we also consume other phytochemicals which may poten-
tiate its availability to systemic circulation for action. This
hypothesis is supported by a study done by Agarwal et al. on
a human cohort. The results revealed that although vitamin
C supplement did not help to decrease the progression of
carotid artery intima-media thickness (IMT) in CVDs like
atherosclerosis, dietary vitamin C did [105]. In contrast to the
beneficial action of vitamin C to alleviate CVD symptoms,
there is some controversy because of the results of the clinical
trial which oppose this fact. For instance, a clinical trial
done by Ward et al. showed that although monotherapy of
vitamin C (for 6 weeks) decreases the systolic blood pressure
in hypertensive subjects, combination therapy of vitamin
C and grapes seed polyphenol increased it. Moreover, the
endothelium independent and dependent vasorelaxation as
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well as oxidative stress marker were not significantly different
from vitamin C/grape seed polyphenol therapy as compared
to a hypertensive individual without therapy. This finding
recommends that hypertensive individuals on vitamin C and
polyphenol supplements therapy should take the necessary
precaution [106].
9.1.2. Vitamin E. Various studies have been carried out
to examine the beneficial effect of vitamin E on CVDs.
Serbinova et al. compared the effect of palm oil vitamin
E with tocopherol alone and found that palm oil vitamin
E was comparatively more successful in safeguarding the
cardiac ischemia-reperfusion damage in the isolated heart
[107]. A recent meta-analysis study done by Ashor et al.
[108] to observe the potency of vitamins on atrial stiffness in
adults disclosed that antioxidant vitamins possess a beneficial
effect by reducing arterial stiffness. Moreover, the efficacy
was dependent on the duration of treatment and dose sup-
plemented. Those subjects having reduced levels of vitamin
E in the blood attained an improved pharmacological effect
from this intervention. In another double-blind, placebo-
controlled study performed by Stephens et al. [109] on a
coronary disease patient, it was found that 400 or 800 IU
per day dose of vitamin E notably decreased the incidence
of nonfatal myocardial infarction in study subjects.
9.2. Failure of Antioxidant Vitamin Therapy to Revert the
CVDs. Although considerable research supports the fact
that antioxidants possess therapeutic benefit to fight against
disease progression, however, clinical trials are unsuccess-
ful in showing the benefit [110]. Hasty et al. found that
vitamin E supplementation for 12 weeks was not successful
in alleviating the oxidative damage in western-type diet
fed low density lipoprotein receptor knockout (LDLR−/−)
mice model of obesity/hyperlipidemia. Although diet was
enough to drastically increase the plasma lipid profile like
free fatty acid, triglyceride, and total cholesterol (a marker of
atherogenesis) in LDLR−/− obese mice with respect to lean
mice, there was no beneficial effect observed after supple-
mentation of vitamin E. Furthermore, there was no reduction
in the urinary isoprostanes (a biomarker of oxidative stress)
levels suggesting that vitamin E does not account for the
cardioprotective effect [111]. A human clinical trial done in
730 volunteers (either sex, ≥65 years) for more than 20 years
demonstrated that lower vitamin C supplementation was
associatedwith highmortality rate by stroke in elderly people.
However, there was no remarkable link between vitamin C
diet status and CHD [112]. Similarly, another human clinical
trial done in a larger population (6996men and 2545women)
also showed that vitamin E had no beneficial effect on
cardiovascular outcomes in patients who are more prone to
cardiovascular events even after treatment for a long period
of 4.5 years [113].
9.3. Pharmacological Agent. Various pharmacology agents
such as statins and angiotensin-converting enzyme (ACE)
inhibitors show pleiotropic effects to halt the oxidative stress.
Particularly in the myocardium, oxidative stress and cell
signaling proteins like Rac, Rho, and Ras are responsible
for the cardiac hypertrophic response [114]. A recent in
vivo investigation revealed that phagocyte-type Nox could
be a potential source of ROS in the myocardium [115].
Nox-dependent ROS production seems to be linked with
cardiac hypertrophy mediated by pressure overload [116]
and angiotensin II infusion [117]. Even though the principal
effect of statin therapy in CVDs is mainly vascular, in vivo
studies recommend that there are also protective effects on
the myocardium. Since Rac1 is essential for Nox function
and cardiac hypertrophy resulted to some extent by oxidative
stress, probably the statins could reduce cardiac hypertrophy
by antioxidant pathway. Particularly, statins were successful
in blocking angiotensin II-mediated oxidative injury in a
rat model of cardiac hypertrophy [118]. Also, this activity of
statins was seen in a clinical trial done in a cardiac hypertro-
phy subject that presented with hypercholesterolemia [119].
In a patient with heart failure, Nox mediated ROS generation
raised in the left ventricular myocardium and associated with
the rise in Rac1 GTPase activity, whereas statin therapy was
able to reduce Rac1 activity in the heart [120].
9.3.1. Statins. Statins category medicines are not a direct
scavenger of ROS; however, they act in an indirect way
by hindering the 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG CoA) reductase pathway involved in cholesterol
synthesis. Metabolism with HMGCoA reductase leads to the
production of intermediate pyrophosphates, considered as a
crucial point for O
2
∙− formation via Nox. The therapeutic
effect of statins to lower the occurrence of CVDs is achieved
by their capacity to promote endothelial nitric oxide synthase
(eNOS) expression as well as antioxidant nature [118, 121–
123]. Factors causing endothelial damage involve ROS such
as oxidized-LDL and hypoxia can reduce the expression of
eNOS whereas statins group medicine can reverse the eNOS
downregulation, highlighting their ability to ameliorate the
vessel NO bioavailability and atherosclerotic plaque stability
[124–126]. Furthermore, statins also block tumor necrosis
factor-𝛼 (TNF-𝛼) mediated downregulation of eNOS [127].
Stimulation of angiotensin II hormone will further activate
Rac1 and ADP-ribosylation factor 6 (ARF6), a controller
of NADPH oxidase function. ARF6 is crucial for ROS
production because, in the knocked down situation of this
GTPase, angiotensin II cannot stimulate O
2
∙− (superoxide
anion) generation. Likewise, ARF6 also regulates NADPH
oxidase 1 (Nox1) expression [128]. A study done by Copaja
et al. showed that induction of cardiac myofibroblasts and
fibroblasts apoptosis by simvastatin followed a cholesterol
synthesis independent pathway but was dependent on Rho
GTPases protein isoprenylation. On comparison, cardiac
myofibroblasts were less sensitive to apoptosis induction than
cardiac fibroblasts by simvastatin. Therefore, it is likely that
simvastatin could circumvent harmful cardiac remodeling
followed by some fibrotic restoration of the injured tissues
[129]. Taken together, the abovementioned beneficial role of
statins in prevention of coronary heart disease can promote
the development of statin therapy against ROS mediated
CVDs.
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9.3.2. ACE Inhibitors. ACE is an enzyme that metabolizes
angiotensin I to angiotensin II. ACE inhibitors were designed
to treat hypertension. During arterial wall remodeling,
increased angiotensin II activity leads to thickening of the
tunica media and narrowing of the vessel diameter, a key
feature of atherosclerosis [130, 131]. In particular, increased
angiotensin II level is associated with the proportional release
of vascular O
2
∙− [132]. In a rabbit model of hypercholes-
terolemia, it was observed that O
2
∙− bioavailability was
decreased in thoracic aorta due to the antioxidative activity
of NO [133]. In contrast, NO concentration can decrease after
reaction with O
2
∙−, thereby worsening the atheroma plague
formation [134]. Although eNOS and neuronal NOS control
normal metabolic functions, upregulation of inducible NOS
leads to enhanced production of NO displaying deleterious
inflammatory responses by forming peroxynitrite by NO
and superoxide [135]. Circulating angiotensin II level can be
enhanced by angiotensin II type I receptor blocker (ARB)
leading to stimulation of angiotensin II type II receptors
followed by vasodilation due to NO production [136, 137]. A
clinical trial in hypertensive patients undergoing candesartan
(a type of ARB) therapy displayed remarkable diminishing
of carotid artery intima-media thickness, mainly because of
augmented NO production as well as decreased oxidative
stress [136]. Likewise, cotreatment of ACE and ARB inhibitor
showed a synergistic inhibitory action against oxidative stress
in a balloon-injured rat carotid artery [138].
10. Conclusions
The exact mechanism of CVD is complex and is not yet fully
understood. ROS plays an important role in the progression
and development of CVD. There is a link between ROS and
the pathophysiology of CVD. We have developed a greater
understanding of production of ROS, detection of ROS,
and therapeutic strategy to prevent production of ROS and
cardiovascular disease. However, more works to improve the
detection and treatment of the ROSmediated dysfunction are
necessary in the upcoming days.
Competing Interests
The authors declare that they have no competing interests.
Authors’ Contributions
All the authors contributed equally to this review.
References
[1] G. Vogiatzi, D. Tousoulis, and C. Stefanadis, “The role of oxida-
tive stress in atherosclerosis,”Hellenic Journal of Cardiology, vol.
50, no. 5, pp. 402–409, 2009.
[2] N. Panth, S.-H. Park, H. J. Kim, D.-H. Kim, and M.-H.
Oak, “Protective effect of Salicornia europaea extracts on high
salt intake-induced vascular dysfunction and hypertension,”
International Journal of Molecular Sciences, vol. 17, no. 7, article
1176, 2016.
[3] H. Bayir, “Reactive oxygen species,” Critical Care Medicine, vol.
33, no. 12, pp. S498–S501, 2005.
[4] T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, and T. Mu¨nzel,
“Endothelial dysfunction, oxidative stress, and risk of car-
diovascular events in patients with coronary artery disease,”
Circulation, vol. 104, no. 22, pp. 2673–2678, 2001.
[5] L. Zuo, L. T. Zhou, B. K. Pannell, A. C. Ziegler, and T. M. Best,
“Biological and physiological role of reactive oxygen species—
the good, the bad and the ugly,” Acta Physiologica, vol. 214, no.
3, pp. 329–348, 2015.
[6] M. B. Reid, “Redox modulation of skeletal muscle contraction:
what we know andwhat we don’t,” Journal of Applied Physiology,
vol. 90, no. 2, pp. 724–731, 2001.
[7] S. K. Wattanapitayakul and J. A. Bauer, “Oxidative pathways
in cardiovascular disease: roles, mechanisms, and therapeutic
implications,” Pharmacology andTherapeutics, vol. 89, no. 2, pp.
187–206, 2001.
[8] M. P. Murphy, “How mitochondria produce reactive oxygen
species,” Biochemical Journal, vol. 417, no. 1, pp. 1–13, 2009.
[9] D. B. Zorov, M. Juhaszova, and S. J. Sollott, “Mitochondrial
reactive oxygen species (ROS) and ROS-induced ROS release,”
Physiological Reviews, vol. 94, no. 3, pp. 909–950, 2014.
[10] D. E. Handy and J. Loscalzo, “Redox regulation of mitochon-
drial function,” Antioxidants & Redox Signaling, vol. 16, no. 11,
pp. 1323–1367, 2012.
[11] Y. J. H. J. Taverne, A. J. J. C. Bogers, D. J. Duncker, and
D. Merkus, “Reactive oxygen species and the cardiovascular
system,” Oxidative Medicine and Cellular Longevity, vol. 2013,
Article ID 862423, 15 pages, 2013.
[12] T. M. Paravicini and R. M. Touyz, “NADPH oxidases, reactive
oxygen species, and hypertension: clinical implications and
therapeutic possibilities,” Diabetes Care, vol. 31, supplement 2,
pp. S170–S180, 2008.
[13] C. H. Coyle, L. J. Martinez, M. C. Coleman, D. R. Spitz, N. L.
Weintraub, and K. N. Kader, “Mechanisms of H
2
O
2
-induced
oxidative stress in endothelial cells,” Free Radical Biology and
Medicine, vol. 40, no. 12, pp. 2206–2213, 2006.
[14] R. Scherz-Shouval and Z. Elazar, “ROS, mitochondria and the
regulation of autophagy,”Trends in Cell Biology, vol. 17, no. 9, pp.
422–427, 2007.
[15] K. Bedard and K.-H. Krause, “The NOX family of ROS-
generatingNADPHoxidases: physiology and pathophysiology,”
Physiological Reviews, vol. 87, no. 1, pp. 245–313, 2007.
[16] J. Kuroda, T. Ago, S. Matsushima, P. Zhai, M. D. Schneider, and
J. Sadoshima, “NADPH oxidase 4 (Nox4) is a major source of
oxidative stress in the failing heart,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 107, no.
35, pp. 15565–15570, 2010.
[17] L. Zuo, S. Pasniciuc, V. P. Wright, A. J. Merola, and T. L.
Clanton, “Sources for superoxide release: lessons from blockade
of electron transport, NADPH oxidase, and anion channels in
diaphragm,” Antioxidants and Redox Signaling, vol. 5, no. 5, pp.
667–675, 2003.
[18] Y. Taniyama and K. K. Griendling, “Reactive oxygen species in
the vasculature: molecular and cellularmechanisms,”Hyperten-
sion, vol. 42, no. 6, pp. 1075–1081, 2003.
[19] C. Napoli and L. J. Ignarro, “Nitric oxide and atherosclerosis,”
Nitric Oxide, vol. 5, no. 2, pp. 88–97, 2001.
[20] M. C. Verhaar, P. E. Westerweel, A. J. Van Zonneveld, and T.
J. Rabelink, “Free radical production by dysfunctional eNOS,”
Heart, vol. 90, no. 5, pp. 494–495, 2004.
Advances in Medicine 9
[21] L. C. Jones and A. D. Hingorani, “Genetic regulation of
endothelial function,”Heart, vol. 91, no. 10, pp. 1275–1277, 2005.
[22] M. de la Paz Scribano, M. del Carmen Baez, B. Florencia et
al., “Effects of atorvastatin on oxidative stress biomarkers and
mitochondrial morphofunctionality in hyperfibrinogenemia-
induced atherogenesis,” Advances in Medicine, vol. 2014, Article
ID 947258, 6 pages, 2014.
[23] B. Lipinski, “Pathophysiology of oxidative stress in diabetes
mellitus,” Journal of Diabetes and Its Complications, vol. 15, no.
4, pp. 203–210, 2001.
[24] X.-L. Chen, Q. Zhang, R. Zhao, and R. M. Medford, “Super-
oxide, H
2
O
2
, and iron are required for TNF-𝛼-induced MCP-1
gene expression in endothelial cells: Role of Rac1 and NADPH
oxidase,” American Journal of Physiology—Heart and Circula-
tory Physiology, vol. 286, no. 3, pp. H1001–H1007, 2004.
[25] M. Malinouski, Y. Zhou, V. V. Belousov, D. L. Hatfield, and V.
N. Gladyshev, “Hydrogen peroxide probes directed to different
cellular compartments,” PLoS ONE, vol. 6, no. 1, Article ID
e14564, 2011.
[26] V. V. Belousov, A. F. Fradkov, K. A. Lukyanov et al., “Genetically
encoded fluorescent indicator for intracellular hydrogen perox-
ide,” Nature Methods, vol. 3, no. 4, pp. 281–286, 2006.
[27] S. Dikalov, K. K. Griendling, andD.G.Harrison, “Measurement
of reactive oxygen species in cardiovascular studies,” Hyperten-
sion, vol. 49, no. 4, pp. 717–727, 2007.
[28] J. Zielonka, S. Srinivasan, M. Hardy et al., “Cytochrome c-
mediated oxidation of hydroethidine and mito-hydroethidine
in mitochondria: identification of homo- and heterodimers,”
Free Radical Biology and Medicine, vol. 44, no. 5, pp. 835–846,
2008.
[29] A. E. Dikalova, A. T. Bikineyeva, K. Budzyn et al., “Therapeutic
targeting of mitochondrial superoxide in hypertension,” Circu-
lation Research, vol. 107, no. 1, pp. 106–116, 2010.
[30] S. Dikalov, B. Fink, M. Skatchkov, and E. Bassenge, “Com-
parison of glyceryl trinitrate-induced with pentaerythrityl
tetranitrate-induced in vivo formation of superoxide radicals:
effect of vitamin C,” Free Radical Biology and Medicine, vol. 27,
no. 1-2, pp. 170–176, 1999.
[31] S. Dikalov, M. Skatchkov, B. Fink, and E. Bassenge, “Quan-
tification of superoxide radicals and peroxynitrite in vascular
cells using oxidation of sterically hindered hydroxylamines and
electron spin resonance,”Nitric Oxide, vol. 1, no. 5, pp. 423–431,
1997.
[32] S. I. Dikalov, A. E. Dikalova, and R. P. Mason, “Noninvasive
diagnostic tool for inflammation-induced oxidative stress using
electron spin resonance spectroscopy and an extracellular cyclic
hydroxylamine,” Archives of Biochemistry and Biophysics, vol.
402, no. 2, pp. 218–226, 2002.
[33] M. C. Y. Chang, A. Pralle, E. Y. Isacoff, and C. J. Chang, “A
selective, cell-permeable optical probe for hydrogen peroxide in
living cells,” Journal of the American Chemical Society, vol. 126,
no. 47, pp. 15392–15393, 2004.
[34] E. W. Miller, A. E. Albers, A. Pralle, E. Y. Isacoff, and C. J.
Chang, “Boronate-based fluorescent probes for imaging cellular
hydrogen peroxide,” Journal of the American Chemical Society,
vol. 127, no. 47, pp. 16652–16659, 2005.
[35] S. E. Gomez-Mejiba, Z. Zhai, H. Akram et al., “Immuno-spin
trapping of protein and DNA radicals: ‘tagging’ free radicals to
locate and understand the redox process,” Free Radical Biology
and Medicine, vol. 46, no. 7, pp. 853–865, 2009.
[36] R. P. Mason, “Using anti-5,5-dimethyl-1-pyrroline N-oxide
(anti-DMPO) to detect protein radicals in time and space with
immuno-spin trapping,” Free Radical Biology andMedicine, vol.
36, no. 10, pp. 1214–1223, 2004.
[37] J. Jiang, K. J. Liu, X. Shi, and H. M. Swartz, “Detection of short-
lived free radicals by low-frequency electron paramagnetic
resonance spin trapping in whole living animals,” Archives of
Biochemistry and Biophysics, vol. 319, no. 2, pp. 570–573, 1995.
[38] T. Sano, F. Umeda, T. Hashimoto, H. Nawata, and H. Utsumi,
“Oxidative stress measurement by in vivo electron spin res-
onance spectroscopy in rats with streptozotocin-induced dia-
betes,” Diabetologia, vol. 41, no. 11, pp. 1355–1360, 1998.
[39] F. He and L. Zuo, “Redox roles of reactive oxygen species
in cardiovascular diseases,” International Journal of Molecular
Sciences, vol. 16, no. 12, pp. 27770–27780, 2015.
[40] X. Zhu and L. Zuo, “Characterization of oxygen radical for-
mation mechanism at early cardiac ischemia,” Cell Death &
Disease, vol. 4, no. 9, article e787, 7 pages, 2013.
[41] X.-X. Wang, X.-L. Wang, M.-M. Tong et al., “SIRT6 protects
cardiomyocytes against ischemia/reperfusion injury by aug-
menting FoxO3𝛼-dependent antioxidant defense mechanisms,”
Basic Research in Cardiology, vol. 111, no. 2, pp. 1–19, 2016.
[42] B. Halliwell and M. Whiteman, “Measuring reactive species
and oxidative damage in vivo and in cell culture: how should
you do it and what do the results mean?” British Journal of
Pharmacology, vol. 142, no. 2, pp. 231–255, 2004.
[43] V. Adam-Vizi and C. Chinopoulos, “Bioenergetics and the
formation of mitochondrial reactive oxygen species,” Trends in
Pharmacological Sciences, vol. 27, no. 12, pp. 639–645, 2006.
[44] J.-S. Kim, Y. Jin, and J. J. Lemasters, “Reactive oxygen species,
but not Ca2+ overloading, trigger pH- and mitochondrial
permeability transition-dependent death of adult rat myocytes
after ischemia-reperfusion,” American Journal of Physiology—
Heart and Circulatory Physiology, vol. 290, no. 5, pp. H2024–
H2034, 2006.
[45] M. Rigoulet, E. D. Yoboue, and A. Devin, “Mitochondrial ROS
generation and its regulation: mechanisms involved in H
2
O
2
signaling,” Antioxidants & Redox Signaling, vol. 14, no. 3, pp.
459–468, 2011.
[46] D. Asada, T. Itoi, A. Nakamura, and K. Hamaoka, “Tolerance
to ischemia reperfusion injury in a congenital heart disease
model,” Pediatrics International, 2016.
[47] X. Huang, J. Zhang, J. Liu et al., “C-reactive protein promotes
adhesion ofmonocytes to endothelial cells viaNADPHoxidase-
mediated oxidative stress,” Journal of Cellular Biochemistry, vol.
113, no. 3, pp. 857–867, 2012.
[48] H.-H. Lee, K. R. Paudel, and D.-W. Kim, “Terminalia chebula
fructus inhibits migration and proliferation of vascular smooth
muscle cells and production of inflammatory mediators in
RAW 264.7,” Evidence-Based Complementary and Alternative
Medicine, vol. 2015, Article ID 502182, 10 pages, 2015.
[49] K. R. Paudel, N. Panth, and D.-W. Kim, “Circulating endothelial
microparticles: a key hallmark of atherosclerosis progression,”
Scientifica, vol. 2016, Article ID 8514056, 9 pages, 2016.
[50] R. M. Touyz, A. M. Briones, M. Sedeek, D. Burger, and A.
C. Montezano, “NOX isoforms and reactive oxygen species in
vascular health,” Molecular Interventions, vol. 11, no. 1, pp. 27–
35, 2011.
[51] T. Akasaki, Y. Ohya, J. Kuroda et al., “Increased expression
of gp91phox homologues of NAD(P)H oxidase in the aortic
media during chronic hypertension: Involvement of the renin-
angiotensin system,” Hypertension Research, vol. 29, no. 10, pp.
813–820, 2006.
10 Advances in Medicine
[52] G. Gordillo, H. Fang, H. Park, and S. Roy, “Nox-4-dependent
nuclear H2O2 drives DNA oxidation resulting in 8-OHdG
as urinary biomarker and hemangioendothelioma formation,”
Antioxidants and Redox Signaling, vol. 12, no. 8, pp. 933–943,
2010.
[53] D. Harrison, K. K. Griendling, U. Landmesser, B. Hornig, and
H. Drexler, “Role of oxidative stress in atherosclerosis,” The
American Journal of Cardiology, vol. 91, no. 3, pp. 7–11, 2003.
[54] D. G. Harrison, “Cellular and molecular mechanisms of
endothelial cell dysfunction,” The Journal of Clinical Investiga-
tion, vol. 100, no. 9, pp. 2153–2157, 1997.
[55] M. Y. White, A. V. G. Edwards, S. J. Cordwell, and J. E. Van
Eyk, “Mitochondria: a mirror into cellular dysfunction in heart
disease,” Proteomics: Clinical Applications, vol. 2, no. 6, pp. 845–
861, 2008.
[56] L. K. Sharma, J. Lu, and Y. Bai, “Mitochondrial respiratory com-
plex I: structure, function and implication in human diseases,”
CurrentMedicinal Chemistry, vol. 16, no. 10, pp. 1266–1277, 2009.
[57] E. Yu, P. A. Calvert, J. R. Mercer et al., “Mitochondrial DNA
damage can promote atherosclerosis independently of reactive
oxygen species through effects on smooth muscle cells and
monocytes and correlates with higher-risk plaques in humans,”
Circulation, vol. 128, no. 7, pp. 702–712, 2013.
[58] J. L. Fetterman, M. Holbrook, D. G. Westbrook et al., “Mito-
chondrial DNA damage and vascular function in patients with
diabetes mellitus and atherosclerotic cardiovascular disease,”
Cardiovascular Diabetology, vol. 15, no. 53, pp. 1–7, 2016.
[59] I. Fleming, U. R. Michaelis, D. Bredenko¨tter et al.,
“Endothelium-derived hyperpolarizing factor synthase
(cytochrome P450 2C9) is a functionally significant source
of reactive oxygen species in coronary arteries,” Circulation
Research, vol. 88, no. 1, pp. 44–51, 2001.
[60] N. R. Madamanchi and M. S. Runge, “Mitochondrial dysfunc-
tion in atherosclerosis,” Circulation Research, vol. 100, no. 4, pp.
460–473, 2007.
[61] S. W. Ballinger, C. Patterson, C. A. Knight-Lozano et al., “Mito-
chondrial integrity and function in atherogenesis,” Circulation,
vol. 106, no. 5, pp. 544–549, 2002.
[62] S. DiMauro and E. A. Schon, “Mitochondrial respiratory-chain
diseases,”TheNew England Journal of Medicine, vol. 348, no. 26,
pp. 2656–2668, 2003.
[63] P. S. Brookes, Y. Yoon, J. L. Robotham, M. W. Anders, and S.-
S. Sheu, “Calcium, ATP, and ROS: a mitochondrial love-hate
triangle,” American Journal of Physiology—Cell Physiology, vol.
287, no. 4, pp. C817–C833, 2004.
[64] F. Di Lisa and P. Bernardi, “Mitochondrial function and
myocardial aging. A critical analysis of the role of permeability
transition,” Cardiovascular Research, vol. 66, no. 2, pp. 222–232,
2005.
[65] H. Utsumi, K. Yasukawa, T. Soeda et al., “Noninvasive mapping
of reactive oxygen species by in vivo electron spin resonance
spectroscopy in indomethacin-induced gastric ulcers in rats,”
Journal of Pharmacology and Experimental Therapeutics, vol.
317, no. 1, pp. 228–235, 2006.
[66] H.-H. Lee, K. R. Paudel, J. Jeong et al., “Antiatherogenic effect
of Camellia japonica fruit extract in high fat diet-fed rats ,”
Evidence-Based Complementary and Alternative Medicine, vol.
2016, Article ID 9679867, 8 pages, 2016.
[67] K. R. Paudel, U.-W. Lee, and D.-W. Kim, “Chungtaejeon, a
Korean fermented tea, prevents the risk of atherosclerosis in rats
fed a high-fat atherogenic diet,” Journal of Integrative Medicine,
vol. 14, no. 2, pp. 134–142, 2016.
[68] S. Mitra, T. Goyal, and J. L. Mehta, “Oxidized LDL, LOX-1 and
atherosclerosis,” Cardiovascular Drugs andTherapy, vol. 25, no.
5, pp. 419–429, 2011.
[69] K. R. Paudel, R. Karki, and D.-W. Kim, “Cepharanthine inhibits
in vitroVSMCproliferation andmigration and vascular inflam-
matory responses mediated by RAW264.7,” Toxicology in Vitro,
vol. 34, pp. 16–25, 2016.
[70] M. Y. Jun, R. Karki, K. R. Paudel, B. R. Sharma, D. Adhikari, and
D.-W. Kim, “Alkaloid rich fraction from Nelumbo nucifera tar-
gets VSMC proliferation and migration to suppress restenosis
in balloon-injured rat carotid artery,” Atherosclerosis, vol. 248,
pp. 179–189, 2016.
[71] S. Ehara, M. Ueda, T. Naruko et al., “Elevated levels of oxidized
low density lipoprotein show a positive relationship with the
severity of acute coronary syndromes,” Circulation, vol. 103, no.
15, pp. 1955–1960, 2001.
[72] C. Meisinger, J. Baumert, N. Khuseyinova, H. Loewel, and
W. Koenig, “Plasma oxidized low-density lipoprotein, a strong
predictor for acute coronary heart disease events in apparently
healthy, middle-aged men from the general population,” Circu-
lation, vol. 112, no. 5, pp. 651–657, 2005.
[73] S. Baldus, C. Heeschen, T. Meinertz et al., “Myeloperoxidase
serum levels predict risk in patients with acute coronary
syndromes,” Circulation, vol. 108, no. 12, pp. 1440–1445, 2003.
[74] F. S. Apple, L. A. Pearce, A. Chung, R. Ler, andM.M.Murakami,
“Multiple biomarker use for detection of adverse events in
patients presentingwith symptoms suggestive of acute coronary
syndrome,” Clinical Chemistry, vol. 53, no. 5, pp. 874–881, 2007.
[75] D. Kutter, P. Devaquet, G. Vanderstocken, J. M. Paulus, V.
Marchal, and A. Gothot, “Consequences of total and subtotal
myeloperoxidase deficiency: risk or benefit?”Acta Haematolog-
ica, vol. 104, no. 1, pp. 10–15, 2000.
[76] C. Le´culier, N. Couprie, P. Adeleine, P. Leitienne, A. Francina,
and M. Richard, “The effects of high molecular weight- and
low molecular weight-heparins on superoxide ion production
and degranulation by human polymorphonuclear leukocytes,”
Thrombosis Research, vol. 69, no. 6, pp. 519–531, 1993.
[77] G. de Gaetano, C. Cerletti, and V. Evangelista, “Recent
advances in platelet-polymorphonuclear leukocyte interaction,”
Haemostasis, vol. 29, no. 1, pp. 41–49, 1999.
[78] J. Shih, S. A. Datwyler, S. C. Hsu et al., “Effect of collection tube
type and preanalytical handling onmyeloperoxidase concentra-
tions,” Clinical Chemistry, vol. 54, no. 6, pp. 1076–1079, 2008.
[79] G. L. Milne, E. S. Musiek, and J. D. Morrow, “F
2
-isoprostanes
as markers of oxidative stress in vivo: an overview,” Biomarkers,
vol. 10, pp. 10–23, 2005.
[80] B. Shao and J. W. Heinecke, “HDL, lipid peroxidation, and
atherosclerosis,” Journal of LipidResearch, vol. 50, no. 4, pp. 599–
601, 2009.
[81] P. Patrignani, G. Santini, M. R. Panara et al., “Induction of
prostaglandin endoperoxide synthase-2 in human monocytes
associated with cyclo-oxygenase-dependent F2-isoprostane
formation,” British Journal of Pharmacology, vol. 118, no. 5, pp.
1285–1293, 1996.
[82] C. Vassalle, N. Botto, M. G. Andreassi, S. Berti, and A. Biagini,
“Evidence for enhanced 8-isoprostane plasma levels, as index of
oxidative stress in vivo, in patientswith coronary artery disease,”
Coronary Artery Disease, vol. 14, no. 3, pp. 213–218, 2003.
[83] B. Halliwell and C. Y. J. Lee, “Using isoprostanes as biomarkers
of oxidative stress: some rarely considered issues,” Antioxidants
& Redox Signaling, vol. 13, no. 2, pp. 145–156, 2010.
Advances in Medicine 11
[84] L. Zuo, L. Nogueira, and M. C. Hogan, “Reactive oxygen
species formation during tetanic contractions in single isolated
Xenopus myofibers,” Journal of Applied Physiology, vol. 111, no. 3,
pp. 898–904, 2011.
[85] L. Zuo, T. M. Best, W. J. Roberts, P. T. Diaz, and P. D. Wagner,
“Characterization of reactive oxygen species in diaphragm,”
Acta Physiologica, vol. 213, no. 3, pp. 700–710, 2015.
[86] L. Zuo, F. L. Christofi, V. P. Wright, S. Bao, and T. L. Clanton,
“Lipoxygenase-dependent superoxide release in skeletal mus-
cle,” Journal of Applied Physiology, vol. 97, no. 2, pp. 661–668,
2004.
[87] T. Zhou, C.-C. Chuang, and L. Zuo, “Molecular characterization
of reactive oxygen species in myocardial ischemia-reperfusion
injury,” BioMed Research International, vol. 2015, Article ID
864946, 9 pages, 2015.
[88] T. L. Vanden Hoek, C. Li, Z. Shao, P. T. Schumacker, and L. B.
Becker, “Significant levels of oxidants are generated by isolated
cardiomyocytes during ischemia prior to reperfusion,” Journal
of Molecular and Cellular Cardiology, vol. 29, no. 9, pp. 2571–
2583, 1997.
[89] L. B. Becker, T. L. Vanden Hoek, Z.-H. Shao, C.-Q. Li, and
P. T. Schumacker, “Generation of superoxide in cardiomy-
ocytes during ischemia before reperfusion,” American Journal
of Physiology—Heart and Circulatory Physiology, vol. 277, no. 6,
pp. H2240–H2246, 1999.
[90] E. Robin, R. D. Guzy, G. Loor et al., “Oxidant stress during
simulated ischemia primes cardiomyocytes for cell death during
reperfusion,” The Journal of Biological Chemistry, vol. 282, no.
26, pp. 19133–19143, 2007.
[91] J. S. Lane, C. P. Magno, K. T. Lane, T. Chan, D. B. Hoyt, and
S. Greenfield, “Nutrition impacts the prevalence of peripheral
arterial disease in theUnited States,” Journal of Vascular Surgery,
vol. 48, no. 4, pp. 897–904, 2008.
[92] World Cancer Research Fund/American Institute for Cancer
Research, Food, Nutrition and the Prevention of Cancer: A
Global Perspective, American Institute for Cancer Research,
Washington, DC, USA, 1997.
[93] WHO, “Report of the joint WHO/FAO expert consultation.
Diet, nutrition and the prevention of chronic diseases,” WHO
Technical Report Series 916 (TRS 916), 2003.
[94] J. M. Rapola, J. Virtamo, S. Ripatti et al., “Randomised trial of 𝛼-
tocopherol and 𝛽-carotene supplements on incidence of major
coronary events in men with previous myocardial infarction,”
The Lancet, vol. 349, no. 9067, pp. 1715–1720, 1997.
[95] R. B. Singh, G. S. Wander, A. Rastogi et al., “Random-
ized, double-blind placebo-controlled trial of coenzyme Q10
in patients with acute myocardial infarction,” Cardiovascular
Drugs and Therapy, vol. 12, no. 4, pp. 347–353, 1998.
[96] S. Das, H. Otani, N. Maulik, and D. K. Das, “Lycopene,
tomatoes, and coronary heart disease,” Free Radical Research,
vol. 39, no. 4, pp. 449–455, 2005.
[97] J.-F. Su, C.-J. Guo, J.-Y. Wei, J.-J. Yang, Y.-G. Jiang, and Y.-
F. Li, “Protection against hepatic ischemia-reperfusion injury
in rats by oral pretreatment with quercetin,” Biomedical and
Environmental Sciences, vol. 16, no. 1, pp. 1–8, 2003.
[98] K. R. Paudel and N. Panth, “Phytochemical profile and biolog-
ical activity of Nelumbo nucifera,” Evidence-based Complemen-
tary and Alternative Medicine, vol. 2015, Article ID 789124, 16
pages, 2015.
[99] N. Panth, K. R. Paudel, and R. Karki, “Phytochemical profile
and biological activity of juglans regia,” Journal of Integrative
Medicine, vol. 14, 2016.
[100] S. R. Devkota, K. R. Paudel, K. Sharma et al., “Investigation of
antioxidant and anti-inflammatory activity of roots of Rumex
nepalensis,” World Journal of Pharmacy and Pharmaceutical
Sciences, vol. 4, no. 3, pp. 582–594, 2015.
[101] E. E. Nishi, R. Ribeiro Campos, C. Toledo Bergamaschi, V. R. de
Almeida, and D. A. Ribeiro, “Vitamin C prevents DNA damage
induced by renovascular hypertension in multiple organs of
Wistar rats,” Human & Experimental Toxicology, vol. 29, no. 7,
pp. 593–599, 2010.
[102] M. S. Botelho-Ono, H. V. Pina, K. H. F. Sousa, F. C. Nunes,
I. A. Medeiros, and V. A. Braga, “Acute superoxide scavenging
restores depressed baroreflex sensitivity in renovascular hyper-
tensive rats,” Autonomic Neuroscience: Basic and Clinical, vol.
159, no. 1-2, pp. 38–44, 2011.
[103] R. M. Bruno, E. Daghini, L. Ghiadoni et al., “Effect of acute
administration of vitamin C on muscle sympathetic activity,
cardiac sympathovagal balance, and baroreflex sensitivity in
hypertensive patients,” American Journal of Clinical Nutrition,
vol. 96, no. 2, pp. 302–308, 2012.
[104] A. Uzun, U. Yener, O. F. Cicek et al., “Does vitamin C or its
combinationwith vitamin e improve radial artery endothelium-
dependent vasodilatation in patients awaiting coronary artery
bypass surgery?” Cardiovascular Journal of Africa, vol. 24, no. 7,
pp. 255–259, 2013.
[105] M. Agarwal, P. K. Mehta, J. H. Dwyer et al., “Differing relations
to early atherosclerosis between vitamin C from supplements
vs. food in the Los Angeles atherosclerosis study: a prospective
cohort study,”TheOpen CardiovascularMedicine Journal, vol. 6,
no. 1, pp. 113–121, 2012.
[106] N. C.Ward, J.M.Hodgson, K.D. Croft,V. Burke, L. J. Beilin, and
I. B. Puddey, “The combination of vitamin C and grape-seed
polyphenols increases blood pressure: a randomized, double-
blind, placebo-controlled trial,” Journal of Hypertension, vol. 23,
no. 2, pp. 427–434, 2005.
[107] E. Serbinova, S. Khwaja, J. Catudioc et al., “Palm oil vitamin E
protects against ischemia/reperfusion injury in the isolated per-
fused langendorff heart,”Nutrition Research, vol. 12, supplement
1, pp. S203–S215, 1992.
[108] A. W. Ashor, M. Siervo, J. Lara, C. Oggioni, and J. C. Mathers,
“Antioxidant vitamin supplementation reduces arterial stiffness
in adults: a systematic review and meta-analysis of randomized
controlled trials,” Journal of Nutrition, vol. 144, no. 10, pp. 1594–
1602, 2014.
[109] N. G. Stephens, A. Parsons, P. M. Schofield et al., “Randomised
controlled trial of vitamin E in patients with coronary disease:
cambridgeHeart Antioxidant Study (CHAOS),”TheLancet, vol.
347, no. 9004, pp. 781–786, 1996.
[110] K. Goszcz, S. J. Deakin, G. G. Duthie, D. Stewart, S. J. Leslie, and
I. L. Megson, “Antioxidants in cardiovascular therapy: panacea
or false hope?” Frontiers in Cardiovascular Medicine, vol. 2,
article 29, pp. 1–22, 2015.
[111] A. H. Hasty, M. L. Gruen, E. S. Terry et al., “Effects of vitamin
E on oxidative stress and atherosclerosis in an obese hyperlipi-
demic mouse model,” The Journal of Nutritional Biochemistry,
vol. 18, no. 2, pp. 127–133, 2007.
[112] C. R. Gale, C. N.Martyn, P. D.Winter, and C. Cooper, “Vitamin
C and risk of death from stroke and coronary heart disease in
cohort of elderly people,” The British Medical Journal, vol. 310,
no. 6994, pp. 1563–1566, 1995.
[113] S. Yusuf, G. Dagenais, J. Pogue, J. Bosch, and P. Sleight,
“Vitamin E supplementation and cardiovascular events in high-
risk patients.TheHeart Outcomes Prevention Evaluation Study
12 Advances in Medicine
Investigators,” The New England Journal of Medicine, vol. 342,
no. 3, pp. 154–160, 2000.
[114] J. Thorburn, S. Xu, and A. Thorburn, “MAP kinase- and Rho-
dependent signals interact to regulate gene expression but not
actin morphology in cardiac muscle cells,” The EMBO Journal,
vol. 16, no. 8, pp. 1888–1900, 1997.
[115] J. K. Bendall, A. C. Cave, C. Heymes, N. Gall, and A. M. Shah,
“Pivotal role of a gp91(phox)-containing NADPH oxidase in
angiotensin II-induced cardiac hyper-trophy in mice,” Circula-
tion, vol. 105, pp. 293–296, 2002.
[116] J.-M. Li, N. P. Gall, D. J. Grieve, M. Chen, and A. M. Shah,
“Activation of NADPH oxidase during progression of cardiac
hypertrophy to failure,” Hypertension, vol. 40, no. 4, pp. 477–
484, 2002.
[117] H. Nakagami, M. Takemoto, and J. K. Liao, “NADPH oxidase-
derived superoxide anion mediates angiotensin II-induced car-
diac hypertrophy,” Journal ofMolecular and Cellular Cardiology,
vol. 35, no. 7, pp. 851–859, 2003.
[118] M. Takemoto, K. Node, H. Nakagami et al., “Statins as antioxi-
dant therapy for preventing cardiac myocyte hypertrophy,”The
Journal of Clinical Investigation, vol. 108, no. 10, pp. 1429–1437,
2001.
[119] T. M. Lee, T. F. Chou, and C. H. Tsai, “Association of pravastatin
and left ventricular mass in hypercholesterolemic patients: role
of 8-iso-prostaglandin f2alpha formation,” Journal of Cardiovas-
cular Pharmacology, vol. 40, no. 6, pp. 868–874, 2002.
[120] C. Maack, T. Kartes, H. Kilter et al., “Oxygen free radical release
in human failing myocardium is associated with increased
activity of rac1-GTPase and represents a target for statin
treatment,” Circulation, vol. 108, no. 13, pp. 1567–1574, 2003.
[121] Cholesterol Treatment Trialists’ (CTT) Collaborators, “Efficacy
and safety of cholesterol-lowering treatment: prospective meta-
analysis of data from 90,056 participants in 14 randomised trials
of statins,”The Lancet, vol. 366, no. 9493, pp. 1267–1278, 2005.
[122] M. H. Shishehbor, M.-L. Brennan, R. J. Aviles et al., “Statins
promote potent systemic antioxidant effects through specific
inflammatory pathways,” Circulation, vol. 108, no. 4, pp. 426–
431, 2003.
[123] K. Node,M. Fujita, M. Kitakaze, M. Hori, and J. K. Liao, “Short-
term statin therapy improves cardiac function and symptoms
in patientswith idiopathic dilated cardiomyopathy,”Circulation,
vol. 108, no. 7, pp. 839–843, 2003.
[124] L. P. Mcquillan, G. K. Leung, P. A. Marsden, S. K. Kostyk,
and S. Kourembanas, “Hypoxia inhibits expression of enos via
transcriptional and posttranscriptionalmechanisms,”American
Journal of Physiology—Heart and Circulatory Physiology, vol.
267, no. 5, pp. 1921–1927, 1994.
[125] M. Endres, U. Laufs, J. K. Liao, andM.A.Moskowitz, “Targeting
eNOS for stroke protection,”Trends in Neurosciences, vol. 27, no.
5, pp. 283–289, 2004.
[126] E. Chavakis, E. Dernbach, C. Hermann, U. F. Mondorf, A.
M. Zeiher, and S. Dimmeler, “Oxidized LDL inhibits vascular
endothelial growth factor—induced endothelial cell migration
by an inhibitory effect on the Akt/endothelial nitric oxide
synthase pathway,” Circulation, vol. 103, no. 16, pp. 2102–2107,
2001.
[127] F. Jantzen, S. Konemann, B. Wolff et al., “Isoprenoid depletion
by statins antagonizes cytokine-induced down-regulation of
endothelial nitric oxide expression and increases no synthase
activity in human umbilical vein EC,” Journal of Physiology and
Pharmacology, vol. 58, no. 3, pp. 503–514, 2007.
[128] M. Bourmoum, R. Charles, and A. Claing, “The GTPase ARF6
controls ROS production to mediate angiotensin II-induced
vascular smooth muscle cell proliferation,” PLoS ONE, vol. 11,
no. 1, Article ID e0148097, 2016.
[129] M. Copaja, D. Venegas, P. Ara´nguiz et al., “Simvastatin induces
apoptosis by a Rho-dependent mechanism in cultured cardiac
fibroblasts and myofibroblasts,” Toxicology and Applied Phar-
macology, vol. 255, no. 1, pp. 57–64, 2011.
[130] K. M. Schmidt-Ott, S. Kagiyama, and M. I. Phillips, “The
multiple actions of angiotensin II in atherosclerosis,”Regulatory
Peptides, vol. 93, no. 1–3, pp. 65–77, 2000.
[131] S. Pushpakumar, S. Kundu, T. Pryor et al., “Angiotensin-II
induced hypertension and renovascular remodelling in tissue
inhibitor of metalloproteinase 2 knockout mice,” Journal of
Hypertension, vol. 31, no. 11, pp. 2270–2281, 2013.
[132] J. B. Laursen, S. Rajagopalan, Z. Galis,M. Tarpey, B. A. Freeman,
and D. G. Harrison, “Role of superoxide in angiotensin II—
induced but not catecholamine-induced hypertension,” Circu-
lation, vol. 95, no. 3, pp. 588–593, 1997.
[133] S. Mu¨ller, I. Ko¨nig, W. Meyer, and G. Kojda, “Inhibition of
vascular oxidative stress in hypercholesterolemia by eccentric
isosorbide mononitrate,” Journal of the American College of
Cardiology, vol. 44, no. 3, pp. 624–631, 2004.
[134] L. J. Ignarro and C. Napoli, “Novel features of nitric oxide,
endothelial nitric oxide synthase, and atherosclerosis,” Current
Diabetes Reports, vol. 5, no. 1, pp. 17–23, 2005.
[135] L. Zuo, M. S. Koozechian, and L. L. Chen, “Characterization of
reactive nitrogen species in allergic asthma,” Annals of Allergy,
Asthma & Immunology, vol. 112, no. 1, pp. 18–22, 2014.
[136] F. Cosentino, C. Savoia, P. De Paolis et al., “Angiotensin II type
2 receptors contribute to vascular responses in spontaneously
hypertensive rats treated with angiotensin II type 1 receptor
antagonists,” American Journal of Hypertension, vol. 18, no. 4,
pp. 493–499, 2005.
[137] H. Ono, S. Minatoguchi, K. Watanabe et al., “Candesartan
decreases carotid intima-media thickness by enhancing nitric
oxide and decreasing oxidative stress in patients with hyperten-
sion,” Hypertension Research, vol. 31, no. 2, pp. 271–279, 2008.
[138] S. Yagi, T. Morita, and S. Katayama, “Combined treatment
with an AT1 receptor blocker and angiotensin converting
enzyme inhibitor has an additive effect on inhibiting neointima
formation via improvement of nitric oxide production and
suppression of oxidative stress,” Hypertension Research, vol. 27,
no. 2, pp. 129–135, 2004.
